CGC · Canopy Growth Corporation

Current Thesis

Federal cannabis rescheduling is a live, accelerating regulatory narrative the DEA's expedited hearing on moving all marijuana, including adult-use, to Schedule III opens 2026-06-29 and must conclude by 2026-07-15. That is a real binary with sector-wide re-rating potential. CGC is a high-beta retail proxy onto that catalyst, but a poor vehicle for it: the stock sits at $1.04 (2026-06-05), within 24% of its 52-week low of $0.84, on a share count that ballooned 163% in a year. Before the hearing even starts, a 2026-06-15 Q4/FY2026 print arrives bundled with restated FY2024/FY2025 financials. This is a LOW-conviction binary-event option, not a momentum setup. There is no base, no MA reclaim, and no trend to ride only event optionality on policy headlines.

Bull Case

• DEA expedited hearing opens 2026-06-29, concludes ≤2026-07-15 and considers downscheduling all marijuana including adult-use to Schedule III (Federal Register, DEA order). A favorable signal re-rates the whole basket; CGC gaps violently on rescheduling headlines given its sub-$2, retail-heavy float.
• Federal ice already broke on 2026-04-28: DOJ/DEA placed FDA-approved marijuana drug products and state-licensed medical marijuana into Schedule III the first Schedule I exit in five decades, driven by Trump's 2025-12-18 executive order on cannabis research.
• Going-concern fear is overstated: the 2026-06-15 restatement is a technical, non-cash reclassification of USD-denominated share-settled warrants issued in FY2024 (equity → liabilities under CAD functional currency). It does not touch cash or the operating business (StockTitan, Motley Fool 2026-05-22).
• Liquidity is adequate: $270.94M cash against $186.07M debt = $84.86M net cash ($0.22/share) as of the latest balance sheet no imminent solvency cliff.
• Revenue base after MTL: the MTL Cannabis acquisition closed 2026-03-16 (~$125M cash + stock) and makes Canopy the leading medical cannabis company in Canada by revenue, adding Quebec pre-rolls, vape, and dried-flower volume.

Bear Case

• Dilution is the structural killer: 377.86M shares outstanding, up 163% year-over-year via repeated ATM raises and the stock-funded MTL deal. Even a positive rescheduling headline gets diluted into a much larger share base; every rally funds the next raise.
• The business still burns: TTM revenue $203.04M against a TTM net loss of $238.19M; not EBITDA-profitable. EPS consensus for the 2026-06-15 print is -$0.06.
• Wrong vehicle for the catalyst: 280E tax relief from adult-use rescheduling flows directly to US plant-touching MSOs (Trulieve TCNNF, Green Thumb GTBIF, Curaleaf CURLF). CGC is Canadian-domiciled; its US exposure runs indirectly through Canopy USA (Acreage/Wana/Jetty).
• Broken price structure: $1.04 (2026-06-05), -38% over 52 weeks, pinned near the $0.84 low, below every meaningful moving average. Dead tape, not a coiled base.
• Restatement still drags the print: even as a non-cash item, restating two prior fiscal years plus interim periods invites scrutiny and headline risk on 2026-06-15, with EPS already negative.
• Squeeze fuel is thin: short interest is 23.02M shares, only ~6.09% of float (MarketBeat, May 2026) moderate, not the high-short setup that powers violent upside squeezes.

Setup & Price Structure

• Last $1.04–$1.06 (2026-06-05); 52-week range $0.84–$2.38; -38% over 52 weeks; market cap ~$482.89M.
• 377.86M shares outstanding (+163% YoY); net cash $84.86M ($0.22/share).
• Trading within 24% of the 52-week low with no higher-low, no breakout, no MA reclaim. There is no momentum structure to buy; the only reason to touch it is policy-event optionality.
• Short interest ~6.09% of float too low to expect a mechanical squeeze; price moves come from headline beta, not borrow pressure.
• Sub-$2 retail proxy → two-sided gaps of 10–30% on single headlines. Sized like a binary option, tight, regardless of archetype.

Catalyst Calendar (next 30 days)

• 2026-06-15 (before open) Q4 & FY2026 results (FYE 2026-03-31) plus restated FY2024/FY2025 and interim periods. CEO Luc Mongeau / CFO Tom Stewart webcast 10:00 ET. EPS consensus -$0.06. ~5 trading days out from 2026-06-07; negative skew. Do not initiate inside the 3-trading-day blackout.
• 2026-06-29 (09:00 ET) DEA expedited rescheduling hearing opens at the DEA facility, Arlington VA; recesses 2026-07-03, reconvenes 2026-07-06, concludes ≤2026-07-15. Considers Schedule III for all marijuana, including adult-use. This is the real theme catalyst, ~22 days out.
• 2026-06-05 (ongoing) White House pushing Congress to preserve hemp CBD legality by amending a broad ban set to take effect later in 2026 (Marijuana Moment). Legislative overhang/tailwind for the CBD side of the complex.
• 2026-05-29 scientific review reports "consistent" anti-tumor effects of marijuana components in glioblastoma (Marijuana Moment), feeding the medical/FDA-product narrative the April reschedule already favors.

What Would Change Our Mind

• Bull confirmation: DEA hearing readouts (NORML/industry parties seated, sympathetic ALJ signal) point toward adult-use Schedule III becoming likely AND the sector basket (MSOS ETF, TCNNF/GTBIF/CURLF) breaks out together cluster confirmation rather than a lone CGC pop. Even then, US MSOs are the cleaner expression.
• Bear confirmation: a daily close below the 52-week low of $0.84; or the 2026-06-15 print reveals accelerating operating cash burn or any going-concern language; or a fresh large ATM/equity raise announcement.
• Catalyst failure: the hearing runs to 2026-07-15 and leaves adult-use in Schedule I, or gets delayed past July the partial-reschedule "sell the news" pattern from 2026-04-28 repeats.
• Vehicle swap: if the theme accelerates, the higher-conviction expression is US plant-touching MSOs that capture 280E relief directly, not a diluted Canadian LP with indirect US exposure.

Correlation Notes

• Moves as a high-beta member of the cannabis basket MSOS ETF, Tilray (TLRY), Aurora (ACB), and US MSOs TCNNF/GTBIF/CURLF and amplifies basket headlines because of its sub-$2 retail float.
• Near-term price is driven by federal policy flow (DEA/DOJ orders, hearing readouts, congressional hemp action), not company fundamentals; the 2026-06-15 print is an idiosyncratic risk layered on top.
• 280E relief is the basket's true upside lever and accrues to US MSOs; CGC captures it only indirectly via Canopy USA, so it tends to lag MSOs on the actual rescheduling payoff while leading them on speculative pre-event squeezes.
• Low correlation to broad equity factors; this is a single-theme, single-headline instrument, which is why sizing stays at option-scale.